For patients who plateau, switching medications can reignite progress
However, the FDA is giving compounders a 60- or 90-day wind-down period, depending on the type of compounding facility, to avoid unnecessary disruption to patient treatment and to help facilitate an orderly transition. The agency intends to exercise enforcement discretion (i.e., not take enforcement action) until April 22 for compounding performed by state-licensed pharmacies and physicians, and until May 22 for FDA-registered outsourcing facilities
JAMA Cardiol 10(1):5970
Yang S, Wang M, Wang T, Sun M, Huang H, Shi X
Wound-healing assay A wound-healing assay was employed to study fibroblast migration
The AI peptide discovery pipeline is compressing the journey from target identification to candidate molecule from decades to months